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Abstract The major process that regulates the amplitude and
kinetics of signal transduction by tyrosine kinase receptors is
endocytic removal of active ligand^receptor complexes from the
cell surface, and their subsequent sorting to degradation or to
recycling. Using the ErbB family of receptor tyrosine kinases we
exemplify the diversity of the down regulation process, and
concentrate on two sorting steps whose molecular details are
emerging. These are the Eps15-mediated sorting to clathrin-
coated regions of the plasma membrane and the c-Cbl-mediated
targeting of receptors to lysosomal degradation. Like in yeast
cells, sorting involves not only protein phosphorylation but also
conjugation of ubiquitin molecules. The involvement of other
molecules is reviewed and recent observations that challenge the
negative regulatory role of endocytosis are described. Finally, we
discuss the relevance of receptor down regulation to cancer
therapy. ß 2001 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Exposure of cells or tissues to a variety of hormones and
growth factors almost invariably leads to disappearance of
speci¢c binding sites from the cell surface. This phenomenon,
which is due to accelerated endocytosis of ligand^receptor
complexes, was termed ‘down regulation’. Down regulation
of one group of receptor tyrosine kinases (RTKs), those
that bind growth factors sharing an epidermal growth factor-
(EGF-) like motif, is one of the most extensively analyzed.
The four members of this group, ErbB-1 through ErbB-4,
are transmembrane proteins whose large extracellular do-
mains bind speci¢c growth factors, whereas their intracellular
domains are endowed with tyrosine kinase activity (reviewed
in [1]). The monomeric forms of ErbB proteins are catalyti-
cally much less active than the ligand-induced dimers, whose
autophosphorylation recruits diverse phosphotyrosine binding
proteins to initiate signal transduction. Because the four ErbB
proteins can form both homo- and heterodimers, and each
receptor can recruit a speci¢c set of signalling proteins, this
con¢guration allows enormous potential for signal diversi¢ca-
tion. Moreover, one ErbB protein, namely ErbB-3 is devoid of
enzymatic activity [2], whereas ErbB-2 seems to function sole-
ly as a low a⁄nity co-receptor [3]. Thus, signalling by ErbB
receptors and their many ligands may be considered in terms
of a layered network whose output depends on combinatorial
interactions.
Uniquely, the ErbB network can be tracked in evolution to
a primordial simple module in worms. The single ErbB ortho-
log of Caenorhabditis elegans is activated by only one ligand,
called Lin3, and it transmits signals primarily through the Ras
pathway. This linear pathway evolved throughout evolution
to form a richly interconnected network, whose complexity
derives from the existence of many ligands and four receptors
capable of forming 10 dimeric combinations. Although signal-
ling down-stream of all four mammalian ErbB proteins is
funneled into the Ras pathway, variation exists in terms of
the speci¢c repertoires of phosphotyrosine binding proteins
that are recruited to each receptor. Moreover, the various
dimeric receptors di¡er in the potency of mitogenic signals,
presumably because each ErbB protein follows a unique path-
way of endocytosis and down regulation. For example, ErbB-1
is rapidly internalized and degraded following activation by
some ligands, but internalization of ErbB-2 and the two neu-
regulin receptors, ErbB-3 and ErbB-4, is relatively slow [4,5].
Because ErbB-3 is devoid of enzymatic activity and this func-
tion is essential for degradation of internalized receptors [6],
this neuregulin receptor recycles back to the plasma mem-
brane, perhaps after unloading its ligand in an endosomal
compartment [7].
A wealth of experimental evidence has established the no-
tion that the kinetics of signalling by ligand-activated recep-
tors determines not only the amplitude of the output but also
its speci¢city (e.g., mitogenesis or di¡erentiation) [8]. Consis-
tent with this paradigm, a mutant ErbB-1 whose endocytosis
is impaired can deliver oncogenic signals [9], and several on-
cogenic animal viruses impair endocytic removal of active
ErbBs from the cell surface. Examples include the E5 protein
of human papilloma virus, which blocks an endosomal ATP-
ase, thus shunting internalized receptors to the recycling path-
way [10]. Poxviruses encode multiple EGF-like ligands that
bind with relatively low a⁄nity to ErbB proteins. However,
because the viral ligands cause only limited receptor down
regulation, their mitogenic potency is enhanced relative to
the mammalian counterpart [11]. Retroviruses present a vari-
ety of mechanisms that help them evade receptor down regu-
lation: Oncogenic Ras proteins appear to slow down the rate
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of internalization, whereas the oncogenic v-ErbB receptor en-
coded by the avian erythroblastosis virus is devoid of a phos-
phorylation site essential for targeting to lysosomal degrada-
tion [12].
Despite their importance, negative regulatory processes are
less understood than the steps involved in signal generation
and propagation to the nucleus. Lessons derived from the
endocytic pathways followed by cargo receptors like the trans-
ferrin receptor (TfR) and the low density lipoprotein (LDL)
receptor are only partially relevant to signalling receptors like
ErbBs. Nevertheless, the list of proteins that participate in
receptor inactivation is steadily increasing and we now begin
to understand their interactions along the endocytic routes.
After dealing with endocytosis in simple eukaryotes, namely
yeast cells, we concentrate on two sorting processes that de-
termine receptor down regulation. These are sorting of recep-
tors to internalization through the clathrin-coated pit and
their later interaction with a machinery that determines lyso-
somal degradation.
2. Lessons from yeast
Genes that are not essential for viability can be deleted
from the yeast genome and thus enable direct examination
of their cellular role. The usefulness of this approach has
been repeatedly exempli¢ed by the isolation of mutant yeast
cells defective in certain steps of endocytosis. Recent ultra-
structural and biochemical approaches suggest that the gen-
eral organization of endocytic tra⁄c inside yeast cells resem-
bles that of mammalian cells. Both early and late endosomes
have been morphologically and biochemically identi¢ed in
yeast [13,14], and the molecular machinery required for vesic-
ular transport in yeast does not seem to be fundamentally
di¡erent from the mammalian machinery [15].
Due to the lack of re¢ned assays to investigate intracellular
post-endocytic steps, this phase is less understood than the
internalization step, which has been thoroughly investigated
in yeast. Interestingly, most yeast transmembrane proteins,
even transporters speci¢c for certain metabolites [15,16],
seem to undergo constitutive endocytosis. However, some of
these endocytic systems display a large increase in the rate of
endocytosis upon varying growth conditions or, in the case of
pheromone receptors, by the addition of a ligand to the
growth medium. Several genes that are potentially essential
for accelerated endocytosis were identi¢ed. Consequently,
some striking similarities and di¡erences between yeast and
mammalian internalization became apparent. One such pro-
tein is the clathrin heavy chain (CHC), a main component of
the clathrin coat and a major player in membrane sorting.
Surprisingly, inactivation of the gene (CHC1), using a temper-
ature sensitive allele, resulted in moderate (50%) reduction in
the rate of a-factor internalization [17]. This partial e¡ect of a
clathrin mutation on endocytosis in yeast may be explained by
the existence of two parallel internalization pathways: a clath-
rin-dependent route as well as a clathrin-independent path-
way, as is the case in mammalian cells.
Another aspect relates to the classical endocytic signals
identi¢ed in mammalian plasma membrane proteins (e.g.
YXXx, where x is a bulky hydrophobic amino acid,
MPXY, and a di-leucine motif). These motifs bind speci¢c
subunits of the AP-2 adapter complex of clathrin, but only
rarely have similar signals been identi¢ed in yeast. One exam-
ple is the linear sequence NPFTD, which is required for li-
gand- and clathrin-dependent endocytosis of the a-factor re-
ceptor [18]. Similarly, the di-leucine motif is required for
endocytosis of the Gap1p permease [19]. In neither case
have the interacting molecules been identi¢ed. However, in
several other cases the endocytic signals identi¢ed in yeast
correspond to motifs required for protein ubiquitination (re-
viewed in [20]). The identi¢ed ubiquitination signals are rela-
tively long acidic sequences. At least in the case of Ste2p,
Ste3p and Fur4p, the acidic nature seems to be modulated
by phosphorylation [21^23]. A phosphorylation-based recog-
nition signal for endocytosis is an appealing possibility in both
yeast and mammals, because ubiquitination and/or endocyto-
sis of many receptors and transporters are often regulated by
ligands, substrates or extracellular nutrients.
Similar to clathrin, the involvement of dynamin in endocy-
tosis has been extensively documented in animal cells, but its
role in yeast is rather limited. Although three dynamin homo-
logs were identi¢ed in yeast, Mgm1p, Vps1p and Dnm1p,
none is absolutely required for internalization of membrane
proteins [24,25]. By contrast, Pan1p, the yeast homolog of the
mammalian EGF-receptor protein substrate Eps15, is essen-
tial for normal endocytosis. The polyvalent structure of Pan1p
implicates it as a key regulator that may transiently recruit
components of the endocytic machinery [26]. An interesting
genetic interaction between Pan1p and the ubiquitin ligase
Rsp5p (the yeast homolog of human Nedd4) has been identi-
¢ed [27]. This WW and HECT domain protein is required for
endocytosis of many yeast proteins [27^29], and although its
biochemical interaction with Pan1p is still uncharacterized,
lessons accumulating with Nedd4 raise the possibility that
Pan1p acts as an adapter connecting the ligase to potential
ubiquitination substrates. That Pan1p may itself be ubiquiti-
nated by Rsp5p is suggested by the observation that Eps15 is
ubiquitinated in mammalian cells [30].
3. Major endocytic routes of membrane receptors
Several morphologically and functionally di¡erent types of
endocytic pathways exist in animal cells. Phagocytosis repre-
sents the uptake of solid particles (s 0.5 W diameter) that
must bind to speci¢c plasma membrane receptors capable of
triggering their own endocytosis, usually by causing the for-
mation of F-actin-driven pseudopods that envelop the bound
particle. On the other hand, pinocytosis enables uptake of
extracellular £uid, macromolecules and solutes bound specif-
ically or non-speci¢cally to the plasma membrane. A third
pathway, receptor-mediated endocytosis, is the selective ad-
sorptive uptake of speci¢c macromolecules bound to plasma
membrane receptors (see Fig. 1). This process involves consti-
tutive formation of small (6 0.2 W diameter) vesicles, which is
usually preceded by the formation of clathrin-coated vesicles
(CCVs). The basic components of the clathrin coat have long
been known [31,32]. A tri-skelion of three CHCs tightly asso-
ciated with three clathrin light chains constitutes the assembly
unit of the polygonal lattice. A hetero-tetramer (AP-2) con-
sisting of two large (K and L) and two small subunits (c2 and
W2) mediates assembly of clathrin cages on the plasma mem-
brane. The L subunit interacts with clathrin [33], whereas the
W2 subunit is capable of binding the tyrosine-based endocytic
signals that mediate internalization of a number of membrane
proteins [34,35].
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An alternative to clathrin-mediated endocytosis involves
specialized forms of rafts, glycosphingolipid and cholesterol-
enriched microdomains, termed caveolae. These are small in-
vaginations that exist on the surface of many cell types. The
£ask-shaped caveolar pit is characteristically 50^80 nm in di-
ameter, highly uniform, and enriched in caveolins, sphingolip-
ids and cholesterol [36^38]. Caveolae are coated with a spiral-
shaped striated coat, which is structurally di¡erent from clath-
rin lattices. Molecules internalized through caveolae (reviewed
in [38]) may travel to the cytoplasm or to the endoplasmic
reticulum. Alternatively, they may be directed to a caveolae
derived tubular/vesicular compartment. Caveolae and clath-
rin-coated pits are specialized to internalize di¡erent types
of molecules. Therefore, caveolae-mediated, and clathrin-
mediated endocytosis are parallel, but non-overlapping, endo-
cytic pathways. Moreover, although several proteins impli-
cated in vesicle tra⁄cking have been localized to caveolar
fractions, it is unclear whether tubular or vesicular caveolae
ever fuse with endosomes originating in coated pits [39].
4. Receptor sorting to the clathrin-coated vesicle
4.1. Exit from caveolae
In quiescent ¢broblasts a relatively large fraction of ErbB-1
is concentrated in caveolae [40^42], but other reports sug-
gested that most of the receptor of overexpressing cells is
Fig. 1. Model of endocytosis of RTKs based on the tra⁄cking of ErbB-1. The major route of endocytosis from the clathrin-coated pit are
marked and the time scale indicated. Unoccupied receptors may be concentrated in caveolae and in non-caveolar regions of the cell surface,
but upon ligand binding and activation of the intrinsic kinase, caveolar receptors translocate out of the caveolae. The potential major players
of caveolar retention and exit are indicated. The mechanism that allows recruitment of the AP2 complex and a clathrin coat are regulated by a
large number of adapters and enzymes, including dynamin and Eps15. Following formation of a clathrin-coated vesicle and its uncoating to
form the early endosome, the second major sorting event takes place. This involves sequestration of active receptors in inner vesicular structure
of the multi vesicular body. On the other hand, receptors whose ligands are released due to the acidic pH of the endosomal compartment, are
directed to tubular structures. The sorting process appears to involve recruitment of c-Cbl, receptor ubiquitination and inward vesicular trans-
port regulated by lipid kinases. Recycling of receptors back to the plasma membrane occurs from most endosomal compartments, but its e⁄-
ciency is gradually reduced, as the compartment becomes deeper in the cytoplasm. Recycling from the tubular portion of the MVB may involve
speci¢c protein kinases such as PKC and Src.
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con¢ned to the low-buoyant density fraction, representing
non-caveolar membrane domains [43]. Structural analysis re-
vealed that the information required for delivery of ErbB-1 to
caveolae is contained within the transmembrane and juxta-
membrane domains of the receptor, distinct from a caveolin-
1 binding domain [44]. In response to EGF, the total number
of surface receptors decreases, along with a decline in the
percentage of EGF receptors in the caveolar fraction. De-
pending on the cell type, it takes 3^30 min for ErbB-1 to leave
caveolae [41]. The rapid exit appears to require autophosphor-
ylation of at least one of the ¢ve major tyrosine residues in the
regulatory domain of the receptor, as well as an intact kinase
activity [45]. In addition to ligand binding, Src family kinases
may control receptor tra⁄c out of caveolae, as a synthetic Src
inhibitor can inhibit receptor exit. Consistent with this model,
overexpression of Src stimulates an increase in the rate of
receptor endocytosis [46]. On the other hand, movement out
of caveolae is inhibited by activators of protein kinase C
(PKC). Interestingly, overexpression and truncation of
ErbB-1 cause a marked phosphorylation of caveolin-1, a ma-
jor component of caveolae whose exact function is still un-
clear [47,48]. Noteworthy is the fact that migration from cav-
eolae is uncoupled to internalization through clathrin-coated
pits, as blocking clathrin mediated endocytosis does not a¡ect
ligand-stimulated depletion of the receptor from the caveolar
fraction.
4.2. Interactions with the AP2 recruiting complex
Natural mutations of the LDL receptor helped uncover the
determinants needed for recruitment of constitutively internal-
izing receptors to the clathrin/AP-2 complex [49], and also
involved a particular tyrosine residue [50]. Since then, a large
variety of internalization signals have been identi¢ed by site-
directed mutagenesis of various cell-surface proteins. Al-
though structurally heterogeneous, these signals may be di-
vided into two groups (reviewed in [35,51]). The ¢rst group
is characterized by an essential tyrosine, which is part of the
motif NPXY or YXXx. Resolution of the crystal structure of
an internalization signal (a YXXx peptide) bound to the W2
subunit of AP2 showed that the peptide assumed an extended
conformation, and speci¢city was conferred by hydrophobic
pockets that bound the tyrosine and the hydrophobic residues
of the peptide [52]. A second group of internalization motifs
typically contains a di-leucine sequence, but in some cases one
of the leucines may be replaced by an isoleucine, valine or an
alanine. In the case of ErbB-1, a stoichiometric complex with
AP2 has been attributed to an internalization signal £anked
by tyrosine residue 974 [53]. However, mutant receptors lack-
ing the putative AP2 binding site can undergo internalization
via clathrin-coated pits [54]. Likewise, the two di-leucine mo-
tifs of ErbB-1 may not play a role in internalization of a full-
length receptor [55^58]. Presumably, internalization signals
allow only low a⁄nity interactions between ErbB proteins
and AP2. This may be su⁄cient for slow constitutive internal-
ization of unoccupied or kinase-defective receptors, but addi-
tional interactions may be involved in ligand-stimulated re-
cruitment into coated pits. In line with this scenario, the
rapid endocytic pathway of ErbB-1 is saturable [59], but sat-
uration of the endocytic pathway for TFRs does not a¡ect
endocytosis of ErbB-1 [60].
4.3. Proteins involved in ligand-regulated recruitment
The three major components of the coated pit are clathrin,
AP2 and dynamin. AP-2 drives clathrin assembly and recruits
the cytoplasmic tails of constitutively internalizing receptors,
as well as ligand-induced receptors. On the other hand, clath-
rin de¢nes the structure of the pit and dynamin is responsible
for ¢ssion of the vesicle from the plasma membrane. This
large GTPase is thought to act as a mechano-enzyme that
mediates the constriction (liberation) of nascent clathrin-
coated pits from the plasma membrane during endocytosis
[61]. In vitro studies indicate that dynamin binds to mem-
brane-embedded phosphoinositides via its PH domain, and
its GTPase activity constructs and fragments membrane tu-
bules capped by clathrin-coated buds [62] (see Fig. 2). A mu-
tant dynamin defective in the GTPase activity blocks ligand-
induced endocytosis of ErbB-1, but constitutive internaliza-
tion is not a¡ected [63]. Unlike constitutively internalizing
receptors, which directly interact with AP2, the endocytic sig-
nals of ligand-induced receptors may be exposed only upon
receptor autophosphorylation. Indeed, kinase activity and a
phosphorylation substrate are required for e⁄cient recruit-
ment of ErbB-1 but not TfR [64]. The identity of the sub-
strate(s) remains unknown. However, recent work by Di-Fiore
and colleagues implicated an AP2 binding protein, Eps15, in
accelerated endocytosis of ErbB-1 [65], and analyses of signal-
ling downstream to the Ral small GTPase attributed a role in
endocytosis to another AP2 binding partner, namely RalBP1
[66,67].
4.3.1. Eps15 and Eps15R. These related proteins are en-
dowed with multiple binding speci¢cities : three copies of the
EH domain bind to NPF motifs of NUMB and other pro-
teins, while the centrally located coiled coil region allows ho-
modimerization or heterodimerization with other coiled coil
proteins such as intersectin. Finally, the COOH-terminal re-
gion, which is characterized by repeated DPF tripeptides
binds the K subunit of the AP2 complex (reviewed in [68]).
Upon activation of ErbB-1, Eps15 is recruited to the plasma
membrane [69] and localizes to coated pits [70]. By electron
microscopy, Eps15 was found to localize to the rim of the
budding-coated vesicle and not to deeper invaginations. The
rim is the growing part of the forming pit. During coat as-
sembly the rim is the only site where Eps15 remains associated
with AP-2, but once clathrin polymerization has taken place,
Eps15 may be excluded from clathrin/AP2 complexes [71].
Consistent with an essential role in receptor-mediated endo-
cytosis, expression of dominant negative mutants of Eps15 or
microinjection of neutralizing antibodies inhibited endocytosis
of both ErbB-1 and TfR [72,73]. However, tyrosine phosphor-
ylation of Eps15 is required exclusively in the process of li-
gand-induced receptor internalization. Thus, an Eps15 mutant
defective in the major tyrosine phosphorylation site (tyrosine
850) speci¢cally inhibited internalization of ErbB-1, but did
not a¡ect internalization of TfR [65]. Because the correspond-
ing phosphopeptide can block internalization, it is conceivable
that following ligand binding and elevated phosphorylation of
tyrosine 850, an unknown phosphotyrosine binding protein
binds to the modi¢ed tyrosine and selectively accelerates re-
cruitment of occupied receptors to the AP2 complex. In con-
clusion, Eps15 may ful¢l a dual role; while it is essential for
endocytosis of constitutively internalizing receptors, its phos-
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phorylation is required only for the rapid, ligand-induced
endocytosis of ErbB-1.
4.3.2. RalBP1 and POB1. Ral is a member of the small
GTP binding protein family [74,75]. The only known e¡ector
protein of Ral, RalBP1, and its own partner POB1, are both
implicated in EGF signalling downstream of Ras [76]. Expo-
sure of cells to EGF or to insulin increases the GTP-bound
active form of Ral through activation of Ras and its e¡ector,
a guanine nucleotide exchange factor for Ral (RalGEF) [77^
79]. Active Ral binds to the C-terminal part of RalBP1, a
putative GTPase of Rac1 and CDC42 [75]. While the rele-
vance of this GAP activity to endocytosis remains unknown,
RalBP1 can e¡ectively recruit the AP2 complex, either directly
or through POB1 and Eps15 (see below). The W2 chain of
AP2, but not other coat proteins, binds to the N-terminus
of RalBP1, and inhibition of these constitutive interactions
blocks endocytosis of both ErbB-1 and TfR [67]. On the other
hand, phosphorylation of POB1, a binding partner of
RalBP1, Eps15 and epsin, another EH domain protein that
participates in clathrin-mediated endocytosis [80], is elevated
by EGF. Thus, recruitment of POB1 to the AP2 complex may
be involved in the ligand-induced pathway. Indeed, deletion
mutants of POB1 can inhibit endocytosis of both ErbB-1 and
the insulin receptor [66]. Presumably, RalBP1 is translocated
to the plasma membrane upon stimulation with EGF and
subsequent activation of Ras and Ral. Once associated with
the plasma membrane, RalBP1 can bind AP2 in a complex
manner that involves not only constitutive and ligand-induced
interactions, but also the intrinsic GTPase activity.
4.3.3. c-Src and Grb2. A role for c-Src in EGFR-mediated
responses has been demonstrated by a number of studies
showing that it is required for EGF-induced mitogenesis
and tumorigenesis [81,82]. The mechanisms by which c-Src
in£uences the biological action of ErbB-1 are diverse: c-Src
may potentiate receptor activity by binding to the receptor
and inducing its phosphorylation, resulting in enhanced
downstream signalling [81]. Alternatively, there may be a mu-
tual catalytic regulation of the receptor and c-Src [83]. How-
ever, accumulating results attribute to Src a role in the endo-
cytic tra⁄cking of RTKs. A signi¢cant fraction of c-Src in
¢broblasts has been found associated with endosomes [84],
and the SH3 domain of c-Src is capable of binding and acti-
vating dynamin [85]. Overexpression of Src leads to an in-
crease in the rate of endocytosis of ErbB-1 [46]. The under-
Fig. 2. Molecules involved in sorting RTKs along the endocytic pathway. The transmembrane receptor is schematically depicted in a complex
with AP2 and a clathrin cage. The interaction of AP2 with the cytoplasmic part of the receptor is mediated by an endocytic signal such as the
YXXx motif, but other adapters, whose engagement depends on tyrosine phosphorylation, may enhance recruitment of the AP2 complex. Mol-
ecules involved in this sorting event, as well as the sorting that occurs in multi vesicular bodies are grouped and schematically presented. The
structural domains are shown in di¡erent colors and their names indicated. The abbreviations used are: CC, coiled coil, C2, a phospholipid
and calcium binding region; D, a region containing DPF repeats; EH, Eps15 homology; FYVE, a PI3P binding; RF, a RING ¢nger domain;
PR, a proline-rich domain; SH, Src homology domain; TK, tyrosine kinase.
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lying mechanism was investigated in cells lacking endogenous
Src family members, or in cells treated with the Src inhibitor
PP1. These experiments showed that endocytosis of the acti-
vated receptor is delayed when Src activity is inhibited [86].
Furthermore, Src activation leads to tyrosine phosphorylation
of the CHC at tyrosine 1477, located at a region involved in
clathrin assembly. Consequently, clathrin undergoes redistrib-
ution to the cell periphery, which may explain how Src is
involved in induced endocytosis [86]. The exact involvement
of another target of RTKs, Grb2, is less understood. How-
ever, this SH3-SH2-SH3 adapter protein (see Fig. 2) binds to
a large variety of cellular proteins, including some e¡ectors of
endocytosis such as POB1, amphiphysin and synaptojanin. In
addition, the SH3 domains of Grb2 interact with dynamin to
activate its GTPase in synergy with phosphoinositides [87].
That some of these interactions are necessary for endocytosis
of ErbB-1 is indicated by the inhibitory e¡ect of a microin-
jected fusion protein containing the SH2 domain of Grb2, or
the corresponding phosphopeptide ligand [88].
5. Sorting in the multivesicular body (MVB)
Once sorted to clathrin-coated vesicles, internalized recep-
tors are delivered within 2^5 min to a tubular^vesicular net-
work located at the cell periphery (Fig. 1). After 10^15 min,
ligand^receptor complexes accumulate in relatively large peri-
nuclear vesicles that contain internal vesicles (MVBs) [89].
These intermediate endosomes are characterized by an accu-
mulation of hydrolytic enzymes, and low internal pH, su⁄-
ciently acidic to dissociate some ligands. Studies performed
with recycling receptors and kinase-defective mutants of
ErbB-1 imply that the MVB is the major site of sorting to
lysosomal degradation. Unlike TFRs and kinase-dead ErbB-1
molecules, which are con¢ned to the vesicular portion of
MVBs, internalized ErbB-1 molecules accumulate in the inner
vesicles of the MVB [6,90]. It is thought that translocation of
active ErbB-1 molecules from the perimeter of the MVB to
internal vesicles requires phosphorylation of an endosomal
substrate that allows, perhaps together with ancillary proteins,
removal of the receptor from the recycling pathway. The
mechanisms underlying regulation of this critical sorting event
currently begin to surface with the identi¢cation of candidate
molecular players we discuss below.
5.1. c-Cbl
Members of the Cbl family of adapter protein are early
prominent substrates for tyrosine phosphorylation by acti-
vated receptors for growth factors, cytokines, and immuno-
globulins (reviewed in [91]). A single Cbl ortholog, Sli1, exists
in nematodes and genetic evidence attributed to it a major
negative regulatory role downstream of Let23, the ErbB or-
tholog of worms [92]. c-Cbl consists of an N-terminal unique
Src homology domain (SH2), which mediates binding to ty-
rosine-phosphorylated receptors [93], and a C-terminal half
that carries a long proline-rich domain and several tyrosine
and serine phosphorylation sites, serving in constitutive and
inducible interactions. A centrally located ring-¢nger (RF)
domain separates the two adapter domains. The RF is missing
or defective in two oncogenic forms of c-Cbl, v-Cbl and 70Z-
Cbl, suggesting a role in the negative function of c-Cbl. In-
terestingly, c-Cbl cannot interact with ErbB-3 and ErbB-4,
two receptors whose ligand-induced down regulation is im-
paired [94]. Indeed, overexpression of c-Cbl enhances down
regulation of ErbB-1 and also increases ligand-induced ubiq-
uitination of this receptor [95]. Recently, c-Cbl was identi¢ed
as a ubiquitin ligase whose RF recruits an ubiquitin-loaded E2
enzyme [12,96], thus establishing its direct role in ubiquitina-
tion of ErbB-1. However, the exact site of action of c-Cbl is a
matter of controversy. Evidence derived from experiments
with yeast (see above), the growth hormone receptor [97]
and blocking ErbB-1 internalization with a dynamin mutant
[98] suggested that ubiquitination may be associated with sort-
ing at the plasma membrane. In addition, translocation of c-
Cbl to the plasma membrane was observed in macrophages
[99]. On the other hand, several groups reported on the endo-
somal localization of c-Cbl and its co-localization with inter-
nalized receptors [95,100,101]. Moreover, the phosphorylation
site of ErbB-1 that allows c-Cbl recruitment and down regu-
lation (tyrosine 1045) has been previously mapped by muta-
genesis to a lysosomal targeting motif [102]. In support with
endosomal sorting, Cbl proteins defective in ubiquitination
enhance recycling of ErbB-1 molecules, probably by inhibiting
c-Cbl’s action [103].
5.2. PI3K
Phosphoinositide 3-kinases phosphorylate inositol lipids at
the 3P position of the inositol ring to generate the 3-phospho-
inositides PI(3)P, PI(3,4)P2 and PI(3,4,5)P3. Attempts to clar-
ify the nature of PI3K involvement in membrane tra⁄c in
mammalian cells have been largely based on the use of inhib-
itors of the catalytic activity of PI3K, such as wortmannin. A
post-endocytic function has been attributed to PI3K in the
case of the receptor for PDGF. Inhibition of PI3K by wort-
mannin or mutagenesis of the PI3K docking site of the PDGF
receptor resulted in altered endocytosis [104]. In both cases
internalized receptors remained con¢ned to peripheral endo-
somal vesicles and escaped translocation to perinuclear endo-
somes. How exactly PI3K drives vesicular tra⁄c is still un-
known, but a recent study revealed necessity of the kinase for
structural integrity of the MVB ([105]. Unlike ErbB-3 and
ErbB-4, which directly interact with PI3K, ErbB-1 seems to
recruit this enzyme only indirectly, either via c-Cbl [106,107],
or through ErbB-3 in a heterodimeric receptor complex [108].
5.3. Hrs
Recent research has shown that one way by which lipid
kinases a¡ect vesicular transport is by interacting with 3-phos-
phoinositide binding modules in a broad variety of proteins.
Speci¢cally, certain FYVE domains bind PI(3)P, whereas cer-
tain pleckstrin homology (PH) domains bind PI(3,4)P2 and
PI(3,4,5)P3. One mammalian FYVE-¢nger protein implicated
in tra⁄cking is Hrs, a hepatocyte growth factor-regulated ty-
rosine kinase substrate [109], which was found to be tyrosine-
phosphorylated also in an EGF-dependent manner. The local-
ization of Hrs to an endosomal compartment seems to depend
on FYVE-PI3P interactions that may cooperate with a second
domain of Hrs [110,111]. Hrs is likely to be a mammalian
homolog of the yeast sorter Vps27p, which is essential for
vacuolar and endocytic tra⁄cking through a pre-vacuolar
compartment [112]. Accordingly, mouse cells that lack Hrs
contain abnormally large early endosomes [113], and Hrs
over-expression leads to the appearance of large structures
containing endosomal markers [110]. These lines of evidence
indicate that Hrs speci¢cally in£uences the dynamics of multi-
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ple endocytic compartments, which merge when the protein is
overexpressed, perhaps due to promotion of vesicle aggrega-
tion or of vesicle fusion [110].
5.4. SNX-1
A yeast two-hybrid system using the core tyrosine kinase
domain of ErbB-1 has identi¢ed SNX1 and implicated the
protein in sorting of the receptor to lysosomal degradation
[114]. SNX-1 speci¢cally interacts with a previously identi¢ed
lysosomal targeting motif, distinct from the c-Cbl’s interaction
site [115]. The putative sorting molecule contains a region of
homology to a yeast vacuolar sorting protein, and overexpres-
sion of SNX-1 decreases the amount of ErbB-1 on the cell
surface as a result of enhanced rates of constitutive and li-
gand-induced degradation. Recent studies revealed the exis-
tence of a large family of SNX-like molecules that are con-
served in yeast and nematodes, and partly associate with the
plasma membrane [116].
5.5. PLCQ
To date there is only indirect evidence for the involvement
of PLCQ in ErbB-1 tra⁄cking. Immortalized ¢broblasts genet-
ically de¢cient in PLCQ do not show signi¢cant e¡ects on
ErbB-1 endocytosis [117]. However, a single tyrosine, which
serves as a PLCQ docking site on the receptor for the ¢bro-
blast growth factor, was found to be important for cellular
tra⁄cking [118]. Another clue for a role in endocytosis came
from the observation that the SH3 domain of PLCQ is able to
bind dynamin in a growth factor inducible manner [119,120].
5.6. PKC
Trans-modulation of ErbB-1 by an active PKC has been
attributed to phosphorylation of a single threonine residue
at the juxtamembrane domain of the receptor [121]. The
modi¢ed receptor displays altered kinase activity and ligand
binding a⁄nity, and its ligand-induced down regulation is
compromised [122]. PKC also a¡ects the unoccupied receptor
through enhanced internalization, which is followed by recy-
cling back to the cell surface [123,124]. By using c-Cbl-induced
ubiquitination as a marker for transfer from early to late
endosomes, it has been recently shown that PKC can inhibit
this process, as well as receptor down regulation and degra-
dation [125]. Apparently, PKC-induced phosphorylation at
threonine 654 is su⁄cient to direct incoming receptors to
the recycling endosome, whereas phosphorylation at tyrosine
residues, through the recruitment of c-Cbl, directs them to the
MVB/late endosome. Currently it is not known how PKC
activity accelerates internalization and inhibits sorting to ly-
sosomal degradation.
6. Relationships between signalling and receptor tra⁄cking
Ligand-induced receptor internalization has long been con-
sidered an attenuation mechanism for signal transduction.
However, mounting evidence suggests more complex relation-
ships as receptors internalized in endosomes, or immobilized
at submembranal domains are capable of signalling in a sur-
prisingly selective manner.
6.1. Signalling from caveolae
In addition to serving as a gate for entry into the cell,
caveolae are the sites where multiple signalling pathways con-
verge. Immunocytochemical, co-immunoprecipitation and
cell-fractionation techniques have shown that a number of
signalling proteins, including RTKs, such as the receptors
for EGF and PDGF, as well as non-receptor kinases and
G-proteins, are found associated with caveolae. This sug-
gested that caveolae compartmentalize enzymatic reactions
essential for signalling from the plasma membrane (reviewed
in [38,126]). The hypothesis that caveolae play a crucial role in
signal transduction by pre-assembling inactive signalling com-
plexes ready for rapid activation in response to extracellular
signals, is based on the following ¢ndings. Caveolin-1 can
interact with the catalytic domain of many resident proteins
of the caveolar fraction through the caveolin sca¡old domain.
These include not only ErbB-1 [44] but also c-Src and the GK
subunit of heterotrimeric G-proteins. In fact, isolated caveolae
contain all essential components required for MAP kinase
activation [127], and in intact cells, both PDGF [42] and
EGF [41] stimulate the recruitment to caveolae of multiple
signal transducing molecules, as well as the migration of the
respective receptor out of caveolae [45]. Depletion of choles-
terol, a major building block of caveolae, causes hyper-acti-
vation of the MAP kinase [128]. By itself, caveolin-1 is a
cholesterol binding protein [129], which has a key role in
controlling the level of cholesterol at the plasma membrane
[130]. A dominant negative mutant of caveolin-1 is unable to
mediate cholesterol tra⁄cking to the plasma membrane, and
it can block the action of H-Ras, but not K-Ras [131]. Lastly,
caveolin is down-regulated and caveolae are reduced in num-
bers in transformed ¢broblasts [132]. In accordance, condi-
tional expression of caveolin-1 can abrogate the transformed
phenotype [133], and antisense depletion of caveolin-1 in in-
tact cells results in cell-transformation [134].
6.2. Signalling from endosomes
Evidence for the existence of highly tyrosine-phosphorylat-
ed ErbB-1 molecules in endosomes came from fractionation of
rat liver [135]. This state has also been visualized directly by
immunoelectron microscopy of A431 cells overexpressing the
receptor [136]. The cytosolic orientation of the tyrosine-phos-
phorylated tail and the presence of an active receptor in endo-
somes for a prolonged period of time suggests that the recep-
tor may continue to signal after internalization. Indeed, when
EGF signalling was analyzed in cells whose endocytosis was
inhibited by a mutant dynamin, enhanced cell proliferation
was observed and analysis of signal transduction components
revealed hyper-phosphorylation of both PLCQ and SHC. Un-
expectedly however, MAP kinase activity was signi¢cantly
reduced, along with phosphorylation of ErbB-1 [63].
Although these observations are in line with some other re-
sults [137,138], some recent observations attributed the e¡ect
on MAP kinase to inhibition of MEK endocytosis [139,140].
Another possible explanation for the attenuated signalling
observed in mutant dynamin expressing cells is the unexpected
loss of high a⁄nity EGF binding sites [141].
While en route to the late endosome, ErbB-1 molecules lose
the ability to stimulate the PLCQ pathway, probably because
components of the pathway become inaccessible [142]. Hrs is
an example for a substrate of ErbB-1 whose accessibility is
enhanced, rather than diminished, upon endocytosis of the
receptor [110]. p21-CIP, an inhibitor of cyclin-dependent pro-
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tein kinases displays a variation on the theme; its activation
by EGF occurs in an endosomal compartment, but no acti-
vation occurs following exposure of cells to another ligand of
ErbB-1, namely TGFK [143]. The enhanced mitogenicity of
this ligand has been attributed to dissociation of ligand^re-
ceptor complexes in the endosomal compartment, which is
followed by receptor recycling [144]. Interestingly, co-expres-
sion of ErbB-2 potentiates EGF signalling to the level
achieved by TGFK, due to heterodimer disintegration in the
early endosome, and receptor recycling to the cell surface
[145,146]. Consistent with this model, formation of ErbB-
1bErbB-2 heterodimers prevents Cbl association with ErbB-1
[147].
7. Cancer therapy: harnessing the endocytic machinery?
Overexpression of ErbB-1 is frequently detected in cancers
of lung, head and neck and in brain tumors (reviewed in
[148,149]). In addition, a constitutively active deletion mutant
of ErbB-1 is abundant in brain tumors [150] and in other
types of cancers [151]. Likewise, ampli¢cation of the erbB-2
gene is associated with a relatively aggressive subtype of
breast, ovary and lung cancers [152]. These clinical observa-
tions and their relationships to poor prognosis has identi¢ed
ErbB proteins as attractive targets for cancer therapy, and one
such agent, a humanized monoclonal antibody to ErbB-2 is
already used to treat metastasizing breast cancers [153]. Im-
portantly, in vitro studies clearly indicate that the oncogenic
action of ErbB-2 depends on its localization at the plasma
membrane [154,155]. Thus, removal of ErbB molecules from
the cell surface by directing them to the endocytic pathway is
expected to inhibit their oncogenic potential. This may be
achieved by using antibodies, modi¢ed ligands, as well as
agents that interfere with translocation and stabilization of
the receptors at the plasma membrane.
7.1. Immunotherapy
Extensive work in animal models has indicated that certain
antibodies can e¡ectively block the tumorigenic growth of
cancer cells overexpressing ErbB-1 or ErbB-2 (reviewed in
[156]). The mechanism underlying the anti-tumorigenic e¡ect
of antibodies to ErbB-2 has been attributed to the recruitment
of immune cells to the tumor through the Fc portion of the
antibody [157]. It is important, however, that antibodies de-
void of the Fc portion are active in tumor inhibition, as long
as their bivalence is maintained. Several observations are con-
sistent with the possibility that the inhibitory e¡ect on cancer
cells is due to antibody-induced removal of the oncoprotein
from the cell surface: antibodies that better down regulate
ErbB-2 are superior as cancer inhibitors [158]. Likewise, ex-
amination of certain combinations of anti-ErbB-2 antibodies
correlated their tumor-inhibitory e¡ect with the ability to de-
grade the oncogenic receptor [159]. Consistent with this sce-
nario, antibodies to ErbB-2 and anti-TFR antibodies co-in-
ternalize through clathrin-coated pits, coated vesicles,
endosomes, and MVBs [160]. The involvement of c-Cbl in
antibody-induced down regulation of ErbB-2 has been ad-
dressed by mutagenesis of the putative site of Cbl binding
to this receptor [161]. The mutant receptor displayed retarded
antibody-induced down regulation, suggesting that tumor-in-
hibitory antibodies utilize, at least in part, the c-Cbl pathway
to degrade ErbB-2.
7.2. Drug-induced degradation of ErbB-2
The benzoquinoid ansamycin antibiotics geldanamycin and
herbimycin A were ¢rst isolated from the culture broth of
several actinomycete species [162,163], and described as inhib-
itors of tyrosine kinase-dependent cell growth [164,165]. These
compounds display inhibitory activity toward numerous cell-
lines, including those over-expressing ErbB-2. This activity is
attributed to the ability of geldanamycin to induce degrada-
tion of ErbB-2 and ErbB-1, as well as of other signal trans-
ducing elements [166,167]. The mechanism underlying gelda-
namycin-induced protein degradation, was shown to involve
the dissociation of a geldanamycin binding protein, the mo-
lecular chaperone Hsp90, or in the case of ErbB-2, its family
member GRP94 [168]. A complex series of proteolytic events
is involved in geldanamycin-induced ErbB-2 degradation, as
was evidenced by the sensitivity of inhibitors of proteasomal
and lysosomal proteases [169]. By using antibodies to both
extracellular and carboxyl-terminal epitopes of ErbB-2, it
was shown that geldanamycin induces fragmentation of
ErbB-2 within the carboxyl-terminal region of the cytoplasmic
domain, and that the resulting transmembrane fragment is
degraded by a mechanism that involves the formation of in-
tracellular vesicles of membranal origin [170].
7.3. Immunotoxins
Antibodies directed against ErbB-2 may serve as useful ve-
hicles for targeting therapeutic agents to tumors. This ap-
proach is attractive because antibodies usually internalize to-
gether with the receptor and introduce the toxic agent into the
cell [158,171,172]. Conjugates of antibodies and toxins have
been used in a preclinical trial as anti-tumor agents [173]. For
example, a Pseudomonas exotoxin lacking its cell binding do-
main was constructed for tumor targeting [174]. Ligands di-
rected against ErbB proteins have also been examined as ben-
e¢cial carriers. For example a betacellulin^Pseudomonas toxin
fusion is e¡ective against cells expressing ErbB-1, but not cells
expressing ErbB-4, probably due to the limited internalizing
capacity of this receptor [175]. Other studies employed anti-
body-containing drug-loaded liposomes that e⁄ciently bind
cancer cells and deliver cytotoxic doses of doxorubicin in a
targeted manner [176], probably through an ability to inter-
nalize [177].
8. Perspectives and concluding remarks
Progression into the cell cycle requires continuous ligand
occupation of growth factor receptors at the cell surface for
as long as 8 h. Removal of the growth factor at any step
within this critical phase, abrogates subsequent commitment
to S phase entry. Recent studies that are reviewed in this
volume begin to reveal the molecular basis for this require-
ment. These include prolonged activation of Ras, up regula-
tion of Myc, and induction of Cyclin D. However, it is al-
ready clear that endocytosis of ligand-occupied receptors, like
ErbB proteins, plays a pivotal role in controlling the duration
of cell activation. The ErbB family of RTKs presents a variety
of mechanisms to control kinetics of signal transduction. For
example, ErbB-3 evolved as a kinase-defective receptor whose
signalling, as well as sorting to degradation, requires a co-
receptor. On the other hand, a major function of the most
oncogenic member of the family, namely ErbB-2, seems to be
prolongation of signal transduction by decelerating ligand dis-
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sociation, inhibiting internalization of ErbB-2-containing het-
erodimeric receptors, and enhancing the rate of receptor
recycling. Another layer of diversity is found at the level of
the ligands. Apparently, the multiple EGF- and neuregulin-
like ligands di¡er not only in their binding speci¢city and
a⁄nity but also in their kinetics of signalling. The underlying
mechanisms involve di¡erential capacity to recruit the ErbB-2
co-receptor to heterodimers, as well as disparate behavior of
the many ligands while they pass through sorting barriers,
such as the clathrin-coated pit and the MVB.
The sorting mechanisms are expected to be resolved in the
near future. It is reasonable to assume that the major players
are already known. However, their sequential engagement and
mutual interactions are currently unclear. It is also conceiv-
able that many of the signalling proteins involved in signal
initiation and propagation will disclose functions as players in
vesicular sorting of active RTKs. Examples include cytoplas-
mic tyrosine kinases (e.g., Src), adapters (e.g., Grb2 and Nck),
and small GTP binding proteins (e.g., Ral). Close relation-
ships between signal initiation and the onset of signal termi-
nation are already exempli¢ed by the sorting molecules Eps15
and c-Cbl, two early substrates of tyrosine phosphorylation.
Future research will also provide an answer to the question of
signalling from the endosomal compartment, an issue that
remains controversial. The exact role of second messengers
like calcium ions, diacylglycerol and inositol phospholipids
will probably become clearer. Likewise, the extent of similar-
ity between yeast and animal cells will have to be de¢ned. One
relevant example is the role, if any, of receptor ubiquitination
as an internalization signal. Partitioning of receptors among
the various endocytic pathways is another important question.
Presumably, constitutive and ligand-activated pathways over-
lap to some extent, but molecular machineries that determine
their remarkably di¡erent rates are still unknown. The rela-
tionships between these two pathways and the stress-induced
endocytic response, which also involves extensive receptor en-
docytosis and degradation, will probably emerge.
Comprehensive understanding of the mechanisms that neg-
atively regulate signal transduction by RTKs have wide range
of implications; from embryonic development to pathological
states, like wound healing, hyper-proliferative diseases and
cancer. Potentially, genes involved in receptor down regula-
tion may act as tumor suppressors. Moreover, drugs that
enhance down regulation or interfere with sorting decisions
are clinically useful. Indeed, humanized antibodies to ErbB-2,
similar chimeric monoclonal antibodies to ErbB-1, as well as
tyrosine kinase inhibitors and drugs that inhibit heat shock
proteins, are already in di¡erent phases of clinical testing or
application. More molecular targets for therapeutic interven-
tion will likely emerge from future studies of receptor down
regulation.
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